253 related articles for article (PubMed ID: 22270142)
1. Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging.
Sugimoto K; Moriyasu F; Shiraishi J; Saito K; Taira J; Saguchi T; Imai Y
Eur Radiol; 2012 Jun; 22(6):1205-13. PubMed ID: 22270142
[TBL] [Abstract][Full Text] [Related]
2. Hypervascular hepatocellular carcinomas: detection with gadoxetate disodium-enhanced MR imaging and multiphasic multidetector CT.
Onishi H; Kim T; Imai Y; Hori M; Nagano H; Nakaya Y; Tsuboyama T; Nakamoto A; Tatsumi M; Kumano S; Okada M; Takamura M; Wakasa K; Tomiyama N; Murakami T
Eur Radiol; 2012 Apr; 22(4):845-54. PubMed ID: 22057248
[TBL] [Abstract][Full Text] [Related]
3. Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis.
Di Martino M; Marin D; Guerrisi A; Baski M; Galati F; Rossi M; Brozzetti S; Masciangelo R; Passariello R; Catalano C
Radiology; 2010 Sep; 256(3):806-16. PubMed ID: 20720069
[TBL] [Abstract][Full Text] [Related]
4. Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma.
Kim DH; Choi SH; Byun JH; Kang JH; Lim YS; Lee SJ; Kim SY; Won HJ; Shin YM; Kim PN
J Hepatol; 2019 Sep; 71(3):534-542. PubMed ID: 31108157
[TBL] [Abstract][Full Text] [Related]
5. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
[TBL] [Abstract][Full Text] [Related]
6. Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging.
Sano K; Ichikawa T; Motosugi U; Sou H; Muhi AM; Matsuda M; Nakano M; Sakamoto M; Nakazawa T; Asakawa M; Fujii H; Kitamura T; Enomoto N; Araki T
Radiology; 2011 Dec; 261(3):834-44. PubMed ID: 21998047
[TBL] [Abstract][Full Text] [Related]
7. A study on the inconsistency of arterial phase hypervascularity detection between contrast-enhanced ultrasound using sonazoid and gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid magnetic resonance imaging of hepatocellular carcinoma lesions.
Wang F; Numata K; Chuma M; Miwa H; Moriya S; Ogushi K; Okada M; Otani M; Inayama Y; Maeda S
J Med Ultrason (2001); 2021 Apr; 48(2):215-224. PubMed ID: 33721130
[TBL] [Abstract][Full Text] [Related]
8. The value of Gd-EOB-DTPA-enhanced MR imaging in characterizing cirrhotic nodules with atypical enhancement on Gd-DTPA-enhanced MR images.
Wang YC; Chou CT; Lin CP; Chen YL; Chen YF; Chen RC
PLoS One; 2017; 12(3):e0174594. PubMed ID: 28355258
[TBL] [Abstract][Full Text] [Related]
9. Characterization of hepatic lesions (≤ 30 mm) with liver-specific contrast agents: a comparison between ultrasound and magnetic resonance imaging.
Takahashi M; Maruyama H; Shimada T; Kamezaki H; Sekimoto T; Kanai F; Yokosuka O
Eur J Radiol; 2013 Jan; 82(1):75-84. PubMed ID: 23116806
[TBL] [Abstract][Full Text] [Related]
10. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
[TBL] [Abstract][Full Text] [Related]
11. Preoperative detection of hepatocellular carcinoma: comparison of combined contrast-enhanced MR imaging and combined CT during arterial portography and CT hepatic arteriography.
Kwak HS; Lee JM; Kim CS
Eur Radiol; 2004 Mar; 14(3):447-57. PubMed ID: 14531005
[TBL] [Abstract][Full Text] [Related]
12. Optimal Combination of Features on Gadoxetate Disodium-enhanced MR Imaging for Non-invasive Differential Diagnosis of Hepatocellular Carcinoma: The JAMP-HCC Study.
Ichikawa S; Motosugi U; Morisaka H; Kozaka K; Goshima S; Ichikawa T
Magn Reson Med Sci; 2021 Mar; 20(1):47-59. PubMed ID: 32101818
[TBL] [Abstract][Full Text] [Related]
13. Contrast-enhanced ultrasonography findings using a perflubutane-based contrast agent in patients with early hepatocellular carcinoma.
Numata K; Fukuda H; Miwa H; Ishii T; Moriya S; Kondo M; Nozaki A; Morimoto M; Okada M; Takebayashi S; Maeda S; Nozawa A; Nakano M; Tanaka K
Eur J Radiol; 2014 Jan; 83(1):95-102. PubMed ID: 24176532
[TBL] [Abstract][Full Text] [Related]
14. Assessment of Gd-EOB-DTPA-enhanced MRI for HCC and dysplastic nodules and comparison of detection sensitivity versus MDCT.
Inoue T; Kudo M; Komuta M; Hayaishi S; Ueda T; Takita M; Kitai S; Hatanaka K; Yada N; Hagiwara S; Chung H; Sakurai T; Ueshima K; Sakamoto M; Maenishi O; Hyodo T; Okada M; Kumano S; Murakami T
J Gastroenterol; 2012 Sep; 47(9):1036-47. PubMed ID: 22526270
[TBL] [Abstract][Full Text] [Related]
15. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver.
Xu PJ; Yan FH; Wang JH; Shan Y; Ji Y; Chen CZ
J Comput Assist Tomogr; 2010 Jul; 34(4):506-12. PubMed ID: 20657216
[TBL] [Abstract][Full Text] [Related]
16. Comparison of enhancement patterns of histologically confirmed hepatocellular carcinoma between gadoxetate- and ferucarbotran-enhanced magnetic resonance imaging.
Okada M; Imai Y; Kim T; Kogita S; Takamura M; Kumano S; Onishi H; Hori M; Fukuda K; Hayashi N; Wakasa K; Sakamoto M; Murakami T
J Magn Reson Imaging; 2010 Oct; 32(4):903-13. PubMed ID: 20882621
[TBL] [Abstract][Full Text] [Related]
17. Is gadoxetate disodium-enhanced MRI useful for detecting local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy?
Watanabe H; Kanematsu M; Goshima S; Yoshida M; Kawada H; Kondo H; Moriyama N
AJR Am J Roentgenol; 2012 Mar; 198(3):589-95. PubMed ID: 22357997
[TBL] [Abstract][Full Text] [Related]
18. Additional value of SPIO-enhanced MR imaging for the noninvasive imaging diagnosis of hepatocellular carcinoma in cirrhotic liver.
Yoo HJ; Lee JM; Lee JY; Kim SH; Kim SJ; Han JK; Choi BI
Invest Radiol; 2009 Dec; 44(12):800-7. PubMed ID: 19838119
[TBL] [Abstract][Full Text] [Related]
19. Gadoxetate Disodium-Enhanced MRI to Differentiate Dysplastic Nodules and Grade of Hepatocellular Carcinoma: Correlation With Histopathology.
Channual S; Tan N; Siripongsakun S; Lassman C; Lu DS; Raman SS
AJR Am J Roentgenol; 2015 Sep; 205(3):546-53. PubMed ID: 26295640
[TBL] [Abstract][Full Text] [Related]
20. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
